|
Miraculins Inc., a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, today announces a non-brokered private placement offering (the “Offering”) of up to 4,500,000 units (“Units”) at a price of $0.07 per Unit for gross proceeds of up to $315,000. Each Unit will be comprised of one common share of the Company (a “Share”) and one Share purchase warrant (a “Warrant”). Each Warrant will entitle the holder to purchase one Share at a price of $0.10 per Share for a period of 18 months from the date the Warrant is issued.
Read More
|
|
Miraculins Inc., a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs is pleased to announce the enrollment of its first patient in the second pivotal study for the Company’s P2V™ prostate cancer diagnostic test. The study will be conducted at the Winnipeg Clinic under the guidance of Principal Investigator, urologist, Dr. Patrick Cho. Samples collected from the study will be tested using recently developed Luminex based assays for both PSP94 and Vitronectin, the two proteins that form the P2V™ test.
Read More
|
|
Miraculins Inc., a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs is pleased to announce that it has executed a license agreement with Mount Sinai Hospital (“MSH”) to acquire the rights to commercialize a portfolio of biomarkers for use in developing diagnostic assays for the early detection of preeclampsia, a disease of growing incidence and the leading cause of maternal and prenatal deaths worldwide. A reliable test for preeclampsia has the potential to be used as a general screen for all pregnant women, representing a market of 6.4 million women annually in the US alone.
Read More
|
|
Company optimizes PSP94 assay and develops Vitronectin assay in urine
Miraculins Inc., a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to update the market on its assay development progress for PSP94 and Vitronectin, the two proteins which comprise the Company’s P2V™ prostate cancer test.
Read More
|
|
Mount Sinai Services to Acquire ASR Materials to Detect Miraculins’ Biomarkers
Miraculins Inc., a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs is pleased to announce that it has signed a letter of intent with Mount Sinai Services (“MSS”) which would allow MSS to acquire FDA regulated commercial products known as Analyte Specific Reagents (“ASRs”) in order to develop in house clinical tests for Miraculins’ growing pipeline of biomarkers.
Read More
|
|
|